Whether it’s starting from scratch to develop an entirely novel vaccine, or testing the effectiveness of an existing vaccination on Covid-19, healthcare companies across the globe have been working day and night to find an effective treatment to immunise patients against the virus.
While the vast majority of these efforts involve small-molecule drugs, Japanese pharma firm Takeda has opted to tackle the infection more directly using blood plasma.
Go deeper with GlobalData
The Osaka-headquartered company has worked on plasma-derived therapies for more than 75 years, and for the past two months has been attempting to develop one such treatment for high-risk patients already infected with SARS-CoV-2, the virus that causes Covid-19.
